ZAP-70 in B cell malignancies

References

• Rosenwald A, Alizadeh A A, Widhopf G, Simon R, Davis R E, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639–1647
   PubMed Web of Science ®Google Scholar
• Wiestner A, Rosenwald A, Barry T S, Wright G, Davis R E, Henrickson S E, et al. ZAP-70 expression identifies a chronic lymphocytic leukemia sub-type with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile. Blood 2003; 101: 4944–4951
   PubMed Web of Science ®Google Scholar
• Damle R N, Ghiotto F, Valetto A, Albesiano E, Fais F, Yan X J, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002; 99: 4087–4093
   PubMed Web of Science ®Google Scholar
• Hamblin T J, Davis Z, Gardiner A, Oscier D G, Stevenson F K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848–1854
   PubMed Web of Science ®Google Scholar
• Kuroyama H, Ikeda T, Kasai M, Yamasaki S, Tatsumi M, Utsuyama M, et al. Identification of a novel isoform of ZAP-70, truncated ZAP kinase. Biochem Biophys Res Commun 2004; 315: 935–941
   PubMed Web of Science ®Google Scholar
• Brdicka T, Kadlecek T A, Roose J P, Pastuzak A W, Weiss A. Intramolecular regulatory switch in ZAP-70: analogy with receptor tyrosine kinases. Mol Cell Biol 2005; 25: 4924–4933
   PubMed Web of Science ®Google Scholar
• Corcoran M M, Parker A, Orchard J A, Davis Z, Wirtz M, Schmitz O, Oscier D. ZAP-70 methylation correlates with ZAP-70 expression in chronic lymphocytic leukaemia. Haematologica 2005; 90: 1078–1088
   PubMed Web of Science ®Google Scholar
• Tomlinson M G, Lin J, Weiss A. Lymphocytes with a complex: adapter proteins in antigen receptor signaling. Immunol Today 2000; 21: 584–591
   PubMedGoogle Scholar
• Steinberg M, Adjali O, Swainson L, Merida P, Di B V, Pelletier L, et al. T-cell receptor-induced phosphorylation of the zeta chain is efficiently promoted by ZAP-70 but not Syk. Blood 2004; 104: 760–767
   PubMed Web of Science ®Google Scholar
• Elder M, Skoda-Smith S, Kadlecek T A, Wang F, Wu J, Weiss A. Distinct T cell developmental consequences in humans and mice expressing identical mutations in the DLAARN motif of ZAP-70. J Immunol 2001; 166: 656–661
   PubMed Web of Science ®Google Scholar
• Ticchioni M, Charvet C, Noraz N, Lamy L, Steinberg M, Bernard A, Deckert M. Signaling through ZAP-70 is required for CXCL12-mediated T-cell transendothelial migration. Blood 2002; 99: 3111–3118
   PubMed Web of Science ®Google Scholar
• Chen L, Widhopf G, Huynh L, Rassenti L, Rai K R, Weiss A, Kipps T J. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609–4614
   PubMed Web of Science ®Google Scholar
• Chen L, Apgar J, Huynh L, Dicker F, Giago-McGahan T, Rassenti L, et al. ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia. Blood 2005; 105: 2036–2041
   PubMed Web of Science ®Google Scholar
• Castro J E, Prada C E, Jose J M, Jung S A, Chen L, Meraz G A, Kipps T J. Expression of ZAP-70 in B cell CLL is associated with a greater capacity to activate NFkB following ligation of surface immunoglobulin. Blood 2004; 104: 769a
   Google Scholar
• Vallat L D, Park Y, Rassenti L, Gribben J G. Temporal gene expression after BCR-crosslinking based upon ZAP-70 related genomic features. Blood 2004; 104: 765a
   Web of Science ®Google Scholar
• Richardson S J, Copplestone J A, Prentice A G. CXCL12 induces actin polymerisation and sustained ERK activation in B-CLL cells expressing ZAP-70. Proceedings of the 9^th Congress of the European Haematology Association 2004, abstract #637.
   Google Scholar
• Lust S, Boelens J, Janssens A, Philippe J, Bracke M, Offner F. CXCL12 induces prolonged ERK phosphorylation in ZAP-70 positive B-CCC. Blood 2004; 104: 526a
   PubMed Web of Science ®Google Scholar
• Richardson S J, Copplestone J A, Prentice A G. CCR7 receptor expression is greater in ZAP-70 positive CLL-B cells and is associated with greater responsiveness to CCLS19 and 21. Proceedings of the 9th Congress of the European Haematology Association 2004, abstract #068.
   Google Scholar
• Nolz J C, Tschumper R C, Pittner B T, Darce J R, Kay N E, Jelinek D F. ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. Leukemia 2005; 19: 1018–1024
   PubMed Web of Science ®Google Scholar
• Orchard J A, Ibbotson R E, Davis Z, Wiestner A, Rosenwald A, Thomas P W, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105–111
   PubMed Web of Science ®Google Scholar
• Rassenti L Z, Huynh L, Toy T L, Chen L, Keating M J, Gribben J G, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893–901
   PubMed Web of Science ®Google Scholar
• Durig J, Nuckel H, Cremer M, Fuhrer A, Halfmeyer K, Fandrey J, et al. ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. Leukemia 2003; 17: 2426–2434
   PubMed Web of Science ®Google Scholar
• Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764–1775
   PubMed Web of Science ®Google Scholar
• Crespo M, Villamor N, Gine E, Colomer D, Marafioti T, Campo E, et al. ZAP-70 expression in human B cells: analysis of normal cells and ALL cells with pro/pre B phenotype. Blood 2004; 104: 194b
   Web of Science ®Google Scholar
• Guillaume N, Alleaume C, Capiod J -C, Pautard B, Desablens B, Claisse J -F, et al. ZAP-70 is constitutively expressed and phosphorylated in B-lineage acute lymphoblastic leukemia cells. Haematologica 2005; 90: 899–905
   PubMed Web of Science ®Google Scholar
• Meade J, Tybulewicz V L, Turner M. The tyrosine kinase Syk is required for light chain isotype exclusion but dispensable for the negative selection of B cells. Eur J Immunol 2004; 34: 1102–1110
   PubMed Web of Science ®Google Scholar
• Schweighoffer E, Vanes L, Mathiot A, Nakamura T, Tybulewicz V. Unexpected requirement for ZAP-70 in pre-B cell development and allelic exclusion. Immunity 2003; 18: 523–533
   PubMed Web of Science ®Google Scholar
• Carreras J, Villamor N, Colomo L, Moreno C, Cajal S, Crespo M, et al. Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. J Pathol 2005; 205: 507–513
   PubMed Web of Science ®Google Scholar
• Herishanu Y, Kay S, Rogowski O, Pick M, Naparstek E, Deutch V R, Polliack A. T-cell ZAP-70 overexpression in chronic lymphocytic leukemia(CLL) correlates with CLL cell ZAP-70 levels, clinical stage and disease progression. Leukemia 2005; 19: 1289–1291
   PubMed Web of Science ®Google Scholar
• Schroers R, Griesinger F, Trumper L, Haase D, Kulle B, Klein-Hitpass L, et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 750–758
   PubMed Web of Science ®Google Scholar
• Sup S J, Domiati-Saad R, Kelley T W, Steinle R, Zhao X, Hsi E D. ZAP-70 expression in B-cell hematologic malignancy is not limited to CLL/SLL. Am J Clin Pathol 2004; 122: 582–587
   PubMed Web of Science ®Google Scholar
• Kim S Z, Chow K U, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steimle-Grauer S A, et al. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk Lymphoma 2004; 45: 2037–2045
   PubMed Web of Science ®Google Scholar
• Krober A, Kienle D, Winkler D, Buhler A, Seiler T, Schopflin C. ZAP-70 expression, VH-mutation status, genomic aberrations and prognosis in chronic lymphocytic leukemia. Blood 2004; 104: 531a
   Google Scholar
• Orchard J A, Davis Z, Ibbotson R, Richards S, Catovsky D, Oscier D. Comparison of ZAP-70,IgVH gene mutational status and CD38 in CLL patients requiring therapy: preliminary report from the UK CLLIV trial. Blood 2003; 102: 33a
   Web of Science ®Google Scholar
• Kienle D, Krober A, Winkler D, Mertens D, Habermann A, Lichter P, et al. High ZAP-70 and differential expression of B-cell receptor related genes in CLL withV3-21 gene usage. Blood 2004; 104: 221a
   Google Scholar
• Bosch F, Crespo M, Villamor N, Muntanola A, Ferrer A, Domingo A, et al. Clinical characteristics and outcome of a large series of patients with CLL, according to ZAP-70 expression. Blood 2004; 104: 8a
   Web of Science ®Google Scholar
• Del Principe M I, Del Poeta G, Venditti A, Buccisano F, Maurillo L, Marini R, et al. Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica 2004; 89: 1468–1475
   PubMed Web of Science ®Google Scholar
• Oppezzo P, Vasconcelos Y, Settegrana C, Jeannel D, Vuillier F, Legarff-Tavernier M, et al. The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. Blood 2005; 106: 650–657
   PubMed Web of Science ®Google Scholar
• Del Giudice I, Osuji N, Matutes E, Morilla A, Morilla R, Burford A, et al. ZAP-70 expression in CLL: correlation with clinical and biological features. Blood 2004; 104: 529a
   Web of Science ®Google Scholar
• Mainou-Fowler T, Dignum H M, Proctor S J, Summerfield G P. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 2004; 45: 455–462
   PubMed Web of Science ®Google Scholar
• Rassenti L, Neuberg D S, Keating M, Gribben J G, Flinn I W, Rai K R, et al. CD38 compared with ZAP-70 or immunoglobulin mutation status as predictor of disease progression in CLL. Blood 2004; 104: 767a
   Web of Science ®Google Scholar
• Admirand J H, Rassidakis G Z, Abruzzo L V, Valbuena J R, Jones D, Medeiros L J. Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. Mod Pathol 2004; 17: 954–961
   PubMed Web of Science ®Google Scholar
• Orchard J A, Davis Z, Parker A, Ibbotson R, Feeley C, Oscier D. ZAP-70 protein expression is negative, and the gene promoter region is methylated, in most cases of MCL and SLVL, and does not correlate with IgVH gene mutational status. 9^th Congress of the European Hematology Association 2004, abstract #638
   Google Scholar
• Chiaretti S, Guarini A, De Proprios M S, Tavolaro S, Intoppa S, Vitale A, et al. ZAP-70 expression in ALL: association with the E2A/PBX1 rearrangement and with the Pre-B stage of differentiation and prognostic implications. Blood 2005, [13 Sep, Epub ahead of print].
   Web of Science ®Google Scholar
• Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol 2003; 21: 841–894
   PubMed Web of Science ®Google Scholar
• Folarin N I, Baker R J, Duke V, Yogashangary B C, Vadikolia C, Wickremasinghe R G. ZAP-70 and lgV mutation status in combination with p53 functional analysis identifies the response of poor prognosis B-CLL patients to conventional cytotoxic agents. Blood 2004; 104: 527a
   Web of Science ®Google Scholar